热门资讯> 正文
Palvella Therapeutics收到FDA孤儿产品开发办公室此前宣布的拨款的初始收益，该拨款支持其正在进行的QTORIN 3.9%雷帕霉素无水凝胶治疗微囊性淋巴畸形的III期SELVA试验
2025-06-09 19:36
- SEI EXCHANGE TRADED FDS SEI Enhanced Low Volatility U.S. Large Cap ETF(SELV) 0
- Palvella Therapeutics Inc. Ordinary Shares(PVLA) 0
- FDA Orphan Products Grants are awarded based on rigorous scientific and technical review by rare disease and regulatory experts
- Up to $2.6 million in non-dilutive funding anticipated over the grant period
- Top-line data from SELVA expected in the first quarter of 2026
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
